Major Changes in Systemic Therapy for Advanced Melanoma.

Abstract

Over the past 5 years, a host of new agents have radically changed the therapeutic landscape in advanced melanoma; gone are the days when the only active agents were interferon and dacarbazine. Nearly 25 years ago, few patients with stage IV melanoma reached 2-year survival; today, these survival curves have risen substantially. At the NCCN 21st Annual Conference, John A. Thompson, MD, discussed updates with longer duration of patient follow-up for immune checkpoint therapies. He also reviewed some of the newer approvals in advanced melanoma, including the combination of ipilimumab and nivolumab, high-dose ipilimumab, the oncolytic virus therapy talimogene laherparepvec, and the molecularly targeted combination of the BRAF and MEK inhibitors vemurafenib and cobimetinib.

• Authors: John A Thompson
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 14 Issue 5 Suppl Pg. 638-40 (05 2016) ISSN: 1540-1413 [Electronic] United States
• PMID: 27226502 (Publication Type: Journal Article)
• Copyright: Copyright © 2016 by the National Comprehensive Cancer Network.

Topics

• Humans
• Melanoma (pathology, therapy)
• Molecular Targeted Therapy (methods)
• Skin Neoplasms (pathology, therapy)